Platinum-resistant ovarian cancer (PROC) is defined by a cancer recurrence within six months of completing platinum-based chemotherapy, a threshold that signals a meaningful biological shift in how the disease behaves.
When ovarian cancer recurs this quickly, it suggests the tumor has developed mechanisms to evade the drugs that once worked. DNA repair pathways may change, cancer cells adapt, and the disease becomes significantly harder to treat with standard approaches. That shift makes platinum-resistant ovarian cancer treatment one of oncology’s most active research areas.
At this stage, your care team will talk about “lines of therapy”, each subsequent treatment course after the first. Clinical trial participation is often prioritized here because standard options offer limited response rates, and clinical trials can provide access to emerging ovarian cancer therapies that standard care doesn’t yet include. Understanding what’s driving resistance and what researchers are doing about it opens real possibilities. The most promising avenues in current research are worth exploring closely.
The most promising avenues in current clinical research
Platinum-resistant ovarian cancer can be challenging to treat, and patients with this diagnosis may face limited options through standard approaches, but a new wave of ovarian cancer research studies is reshaping what’s possible for patients who’ve run out of standard options.
Mirvetuximab soravtansine is the first ADC approved specifically for PROC, delivering chemotherapy directly to tumor cells and sparing healthy tissue.
Immunotherapy combinations are also under active investigation. Researchers are exploring checkpoint inhibitors paired with therapeutic vaccines.
Two additional research directions are gaining momentum:
- Platinum re-sensitization: Experimental agents aim to reverse the resistance mechanisms that make standard chemotherapy ineffective, potentially restoring treatment options patients previously exhausted.
- PARP inhibitor combinations: Moving beyond monotherapy, trials are now testing PARP inhibitors alongside other targeted agents for patients with and without BRCA mutations, broadening eligibility significantly.
Knowing where these trials are actively recruiting is the critical next step, and that’s exactly what we’ll cover next.
Where to find active clinical trials near you
Finding the right ovarian cancer therapy trial requires knowing which databases surface relevant, actively recruiting studies and how to filter them for your location.
ClinicalTrials.gov remains the most comprehensive starting point. ClinicalTrials.gov is a commonly used resource where you may be able to search for trials and filter results by factors such as recruitment status, condition, and location. Setting those filters together dramatically narrows results to trials you can realistically access.
The NCI’s clinical trials search tool adds another layer of value. It’s specifically organized around NCI-Designated Cancer Centers, which tend to host early-phase studies that haven’t yet appeared on broader registries. For patients exploring recurrent ovarian cancer treatment options, these centers are worth prioritizing.
Academic medical centers maintain their own institutional trial listings for ovarian cancer, where patients can find studies currently enrolling new participants. Checking those sites directly closes the gap.
Patient-facing platforms translate dense eligibility criteria into plain language, helping you identify whether a trial’s biomarker requirements match your profile. Understanding which databases and tools can match your specific situation most efficiently is where the next step begins.
Search across multiple registries simultaneously, since no single database captures every actively recruiting study.
Decoding eligibility. What you need to know before applying
Before you apply to clinical trials for platinum-resistant ovarian cancer, understanding eligibility criteria saves you significant time and helps you focus on studies where you’re most likely to qualify.
Eligibility rules exist to protect your safety and ensure researchers gather meaningful data, but they also mean that not every trial is a fit for every patient. Four categories tend to matter most.
- Prior lines of therapy. Most trials specify a minimum and maximum number of previous treatments. A study designed for heavily pre-treated patients may require at least two or three prior regimens, while others cap eligibility at one or two. The number of treatments you’ve received directly shapes which options are open to you.
- Biomarker status. Testing for FRα (Folate Receptor alpha), BRCA1/2, and HRD is increasingly a prerequisite, not an afterthought. Many targeted therapies only enroll patients whose tumors express a specific marker, so confirming your results before searching saves time.
- Organ function and exclusionary criteria. Recent bloodwork, covering kidney, liver, and bone marrow function, is a standard screening prerequisite. Certain medications or recent procedures can also disqualify you temporarily.
Once you understand where you stand on these criteria, washout periods, measurable disease requirements, and geographic feasibility become the next essential filters to work through.
Practical screening criteria
Washout periods and geographic feasibility, will quickly narrow your list to realistic options.
Washout periods refer to the minimum time required between your last treatment and a trial’s start date.. Missing this window is one of the most common reasons patients are screened out after an otherwise strong match.
Geographic feasibility deserves honest consideration. Understanding these logistical demands upfront helps you and your care team build a personalized care plan that balances access with your daily life. This sets you up for the targeted questions you’ll want to bring to your next oncology consultation.
Questions to ask your oncology team about trials
Connecting your online research with your care team’s expertise is the most important step before committing to any trial.
Online databases give you a starting point, but your oncologist can contextualize findings against your specific prognosis of ovarian cancer, including tumor biology, prior treatment response, and overall health status. Come prepared with a focused list of questions rather than a stack of printouts.
Logistical questions matter more than most patients expect. Ask clearly: who covers the cost of the investigational drug versus standard care expenses like imaging or lab work? Trial sponsors typically fund the experimental agent, but out-of-pocket costs vary by institution and insurance plan.
Scientific questions sharpen your understanding of what success actually looks like. Ask what the trial’s primary endpoint is. Progression-Free Survival measures how long disease stays stable, while Overall Response Rate tracks tumor shrinkage. Each tells a different story about benefit.
Personal questions address your contingency plan. Specifically, ask what happens if your cancer progresses while you’re enrolled, whether you can access salvage therapy, exit the trial, or transition back to standard care. These answers inform your next consultation, where you’ll also want to dig into how the trial team manages side effects and what the visit schedule realistically demands of you.
Consultation discussion points
Three conversation topics with your care team will shape everything that follows before you commit to any therapy for ovarian cancer within a trial setting.
Standard of care vs. experimental arm. Ask your oncologist to explain the control arm clearly. Most trials pair a placebo with a standard-of-care backbone treatment.
Side effect management. Trial teams operate under strict adverse-event protocols, but those protocols may differ from what your regular oncologist coordinates day-to-day.
Trial duration and visit cadence. Establish a realistic timeline. How often are scans scheduled, when is blood work drawn, and how many infusion visits per cycle? This calendar directly affects your work, family commitments, and travel logistics. Understanding this point is essential alongside other practical limitations worth weighing before you sign the consent form.
Trust and transparency. Limitations of clinical trials
Clinical trials offer potential benefit, and being informed about their limitations is just as important as understanding what they can offer.
Even the most promising trial carries unknown risks, particularly in early-phase studies where dosing and side effects are still being characterized. For patients with stage 4 ovarian cancer, this distinction matters deeply. Your care team can help you weigh those unknowns against your current options, but it’s worth entering any trial conversation with realistic expectations about what participation can and cannot promise.
Practical barriers also shape the experience. Travel to a trial site, lodging costs, and time away from daily life are real considerations that aren’t always covered by the study. Some patients encounter what’s called a screen failure, meaning they don’t meet the trial’s eligibility criteria after completing the initial screening process. This is common and doesn’t reflect your overall prognosis; it simply means that particular protocol wasn’t the right fit.
A balanced view on outcomes matters here. Trials often focus on progression-free survival or response rates rather than overall cure. Quality of life, managing symptoms, maintaining function, staying connected to what matters, is increasingly a stated goal of modern ovarian cancer research. Understanding that distinction helps you ask better questions. Those questions about risks and realistic outcomes lead naturally into the next important conversation about how trial phases and trial design affect what you can realistically expect from participation.
The bottom line. Key takeaways for patients
Platinum resistance is a turning point where many patients benefit from exploring clinical trials for ovarian cancer.
Start early. Waiting until other treatments are exhausted can limit your eligibility. Resources like ClinicalTrials.gov and the NCI’s ovarian cancer trial listings are practical starting points for building your shortlist.
Get biomarker tested. Testing for markers like FRα is critical to identifying which trials you’re actually eligible for. Without it, you’re searching without a map.
Talk to your care team. Trial protocols vary widely, and your provider can help you assess whether a study’s requirements, endpoints, and risk profile align with your personalized care plan. That conversation should happen before you commit to anything.
Disclaimer: The information provided in this article is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Outcomes4Me is not acting as your caregiver, and any suggestions or guidance offered should not replace the advice of your healthcare provider or qualified medical professional. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding a medical condition.
